Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

Maria Rita Marabeti, Patrizia Cancemi, Ida Pucci, Gianluca Di Cara, Nadia Ninfa Albanese, Maria Rita Marabeti, Rosa Musso, Gianluca Di Cara, Germana Marengo, Ida Pucci-Minafra, Patrizia Cancemi, Gianluca Di Cara, Nadia Ninfa Albanese, Rosa Musso

Research output: Contribution to journalArticle

17 Citations (Scopus)


BACKGROUND:The Human Epidermal Growth Factor Receptor 2 (HER-2), overexpressed in 25-30% of breast carcinomas (BC), is the therapeutic target for trastuzumab, a recombinant humanized monoclonal antibody. The initial response to trastuzumab is often followed by drug-insensitivity within one year. Several hypotheses have been raised to explain this event, but the mechanisms behind the responses to trastuzumab are still unclear. Aim: To study the effects of short and prolonged trastuzumab treatment on the proteomic profiles of HER-2-overexpressing SKBR-3 BC cells.MATERIALS AND METHODS:Cells were treated with trastuzumab to obtain sensitive and resistant clones. The drug effects were evaluated at the phenotypical and proteomic levels.RESULTS:In the trastuzumab-resistant cells the expression of a large amount of proteins, initially affected by treatment, reverted to levels of the untreated cells.CONCLUSION:The results obtained so far illustrate for the first time a large-scale differential protein expression between trastuzumab-treated and untreated cells, and between trastuzumab-sensitive and resistant cells. We believe that the results obtained will help to increase the knowledge of the molecular effects of trastuzumab and will be useful to better-understand the drug resistance mechanisms.
Original languageEnglish
Pages (from-to)489-503
Number of pages15
JournalAnticancer Research
Publication statusPublished - 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.'. Together they form a unique fingerprint.

  • Cite this

    Marabeti, M. R., Cancemi, P., Pucci, I., Cara, G. D., Albanese, N. N., Marabeti, M. R., Musso, R., Cara, G. D., Marengo, G., Pucci-Minafra, I., Cancemi, P., Di Cara, G., Albanese, N. N., & Musso, R. (2013). Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells. Anticancer Research, 33, 489-503.